Sosei Group Corporation operates in the Commercial physical research sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Sosei Group with three other
companies in this sector in Japan:
Takara Bio Inc
sales of 29.38 billion Japanese Yen [US$274.07 million]
of which 90%
was Bio support),
Shin Nippon Biomedical Laboratories Ltd
(17.24 billion Japanese Yen [US$160.89 million]
of which 75%
was Pre-Clinical Business), and
Morishita Jintan Co., Ltd.
(10.97 billion Japanese Yen [US$102.32 million]
of which 71%
was Health Care Business).
Sosei Group reported sales of ¥18.90 billion (US$176.35 million)
March of 2017.
increase of 131.9%
versus 2016, when the company's sales were ¥8.15 billion.
Sales at Sosei Group have increased during each of the previous five years
(and since 2012, sales have increased a total of 2,092%).
Sales of Overseas Pharmaceutical Business saw an increase
136.3% in 2017, from
¥7.95 billion to ¥18.80 billion.
Not all segments of Sosei Group experienced an increase in sales in 2017:
sales of Demestic Pharmaceutical Business fell 48.2% to ¥102.00 million.
(However, this segment's sales were only a very small portion of the company's overall sales).